Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

NCT00110851 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: rosiglitazone
DRUG: metformin
DRUG: PN2034

Sponsor

Wellstat Therapeutics